Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Maleddu

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Current Treatment Options in Oncology|June 27, 2025
Interrupted Systemic Therapy (Drug Holiday) for Metastatic Sarcoma: Is It Safe?Alessandra Maleddu, Cole Wayant
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2023
Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022Breelyn A Wilky, Alessandra Maleddu
Journal of Translational Medicine|May 25, 2011
The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical settingAlessandra Maleddu, Maria A Pantaleo, Margherita Nannini, et al.
Expert Opinion on Therapeutic Targets|March 10, 2011
New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and futureMargherita Nannini, Guido Biasco, Alessandra Maleddu, et al.
Frontiers in Oncology|August 7, 2023
Current therapies and future prospective for locally aggressive mesenchymal tumorsAlessandra Maleddu, Jessica Zhu, Michael Roy Clay, et al.
Cancer Treatment Reviews|December 17, 2008
Gene expression profiling in colorectal cancer using microarray technologies: results and perspectivesMargherita Nannini, Maria Abbondanza Pantaleo, Alessandra Maleddu, et al.
Nuclear Medicine Communications|March 6, 2009
The Response Evaluation Criteria in Solid Tumors: until when?Margherita Nannini, Maria Abbondanz Pantaleo, Alessandra Maleddu, et al.
Cancer Chemotherapy and Pharmacology|January 20, 2009
To widen the setting of cancer patients who could benefit from metronomic capecitabineMargherita Nannini, Elisabetta Nobili, Roberto Di Cicilia, et al.
Oncology Reports|May 9, 2009
Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review)Alessandra Maleddu, Maria A Pantaleo, Margherita Nannini, et al.
Pediatric Blood & Cancer|November 12, 2021
Current approaches to management of bone sarcoma in adolescent and young adult patientsKatrina M Ingley, Alessandra Maleddu, Franel Le Grange, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Current Treatment Options in Oncology|June 27, 2025
Interrupted Systemic Therapy (Drug Holiday) for Metastatic Sarcoma: Is It Safe?Alessandra Maleddu, Cole Wayant
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2023
Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022Breelyn A Wilky, Alessandra Maleddu
Journal of Translational Medicine|May 25, 2011
The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical settingAlessandra Maleddu, Maria A Pantaleo, Margherita Nannini, et al.
Expert Opinion on Therapeutic Targets|March 10, 2011
New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and futureMargherita Nannini, Guido Biasco, Alessandra Maleddu, et al.
Frontiers in Oncology|August 7, 2023
Current therapies and future prospective for locally aggressive mesenchymal tumorsAlessandra Maleddu, Jessica Zhu, Michael Roy Clay, et al.
Cancer Treatment Reviews|December 17, 2008
Gene expression profiling in colorectal cancer using microarray technologies: results and perspectivesMargherita Nannini, Maria Abbondanza Pantaleo, Alessandra Maleddu, et al.
Nuclear Medicine Communications|March 6, 2009
The Response Evaluation Criteria in Solid Tumors: until when?Margherita Nannini, Maria Abbondanz Pantaleo, Alessandra Maleddu, et al.
Cancer Chemotherapy and Pharmacology|January 20, 2009
To widen the setting of cancer patients who could benefit from metronomic capecitabineMargherita Nannini, Elisabetta Nobili, Roberto Di Cicilia, et al.
Oncology Reports|May 9, 2009
Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review)Alessandra Maleddu, Maria A Pantaleo, Margherita Nannini, et al.
Pediatric Blood & Cancer|November 12, 2021
Current approaches to management of bone sarcoma in adolescent and young adult patientsKatrina M Ingley, Alessandra Maleddu, Franel Le Grange, et al.
Pageof 3